Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
Becomes the 1st diagnostics company in India to launch BD MAX MDR TB test
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
There is a fast resurgence in the transplant activities post COVID
FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients
Subscribe To Our Newsletter & Stay Updated
